GILEAD SCIENCES 885823 (Seite 150)
eröffnet am 20.02.06 13:18:36 von
neuester Beitrag 13.02.24 21:17:08 von
neuester Beitrag 13.02.24 21:17:08 von
Beiträge: 3.632
ID: 1.041.671
ID: 1.041.671
Aufrufe heute: 10
Gesamt: 481.691
Gesamt: 481.691
Aktive User: 0
ISIN: US3755581036 · WKN: 885823
60,85
EUR
-2,95 %
-1,85 EUR
Letzter Kurs 22:26:26 Tradegate
Neuigkeiten
| Gilead Sciences Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
22:02 Uhr · Business Wire (engl.)  |
24.04.24 · Shareribs Anzeige |
22.04.24 · Shareribs Anzeige |
18.04.24 · Shareribs Anzeige |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7400 | +26,82 | |
| 10,000 | +25,00 | |
| 6,0000 | +25,00 | |
| 0,6400 | +18,52 | |
| 0,9060 | +14,83 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,7200 | -19,60 | |
| 0,7200 | -22,58 | |
| 4,0000 | -27,27 | |
| 2,7280 | -29,14 | |
| 14,510 | -32,32 |
Beitrag zu dieser Diskussion schreiben
FeedbackIst Ibuprofen tatsächlich gefährlich für Coronavirus-Infizierte?
https://www.welt.de/wissenschaft/article206555049/Ibuprofen-… Pandemie-Szenario mit Millionen Toten: Regierung hätte sich schon 2013 für COVID-19 rüsten können
https://www.epochtimes.de/china/pandemie-szenario-mit-millio…https://www.bbk.bund.de/SharedDocs/Downloads/BBK/DE/Download…
Early Results Dampen Outlook for Experimental COVID-19 Treatment
https://www.fool.com/investing/2020/03/14/early-results-damp… A new paper about a Gilead drug to combat coronavirus has some analysts skittish about success
https://www.statnews.com/pharmalot/2020/03/13/gilead-coronav… List of Countries Forecast 2025
http://www.deagel.com/country/forecast.aspxWie die wohl auf ihre Vorhersagen zur Bevölkerungsentwicklung kommen?
Corona könnte helfen?
Gerüchte gibt es viele:
https://www.veteranstoday.com/2020/03/14/china-us-brought-co…
Aber warum prognostizieren die eine Reduzierung der Bevölkerungszahlen in U.S und D auf 1/3 bis 2025?
Trading Spotlight
Gilead Pops After Coronavirus Drug Helps Cruise Ship Patients In Japan
ALLISON GATLIN 04:32 PM ET 03/13/2020
Shares of GILD stock popped Friday on reportedly promising results for its experimental coronavirus treatment in 14 Americans hospitalized in Japan.
The results are some of the earliest for Gilead Sciences' (GILD) remdesivir, an antiviral that was previously under testing for Ebola virus. Now, the biotech company is hoping to use it to treat Covid-19, a form of coronavirus discovered in December in China.
According to the Wall Street Journal, 14 Americans aboard the Diamond Princess cruise ship who contracted Covid-19 were given remdesivir intravenously once a day for 10 days. As of Friday, all 14 were still alive and more than half had recovered.
Five remain critically ill, Rear Adm. Richard Childs, an assistant surgeon general and lung specialist at the National Institutes of Health, reportedly said. The average age of the 14 patients is 75 and all of them were critically ill. The news sent GILD stock airborne Friday.
"Many of them were probably going to die in a short amount of time, and two weeks later nobody has died and more than half of them have recovered," he said. "It's just absolutely amazing. It's going to take us a while to figure out what the impact of the drug has been."
GILD Stock Rises On Coronavirus Treatment
On the stock market today, GILD stock jumped 3.2%, to 70.75. The biotech stock has been volatile as it seeks a coronavirus treatment. Meanwhile, a broader coronavirus correction has slammed the stock market.
Many are pinning their hopes for Covid-19 treatment on remdesivir. Tests of the potential coronavirus treatment are ongoing in China, Japan and the U.S. Amid the broad correction, GILD stock also has a Relative Strength Rating of 92, putting its stock performance in the top 8% of all stocks.
The Diamond Princess cruise ship docked in Japan on Feb. 4 after officials learned a prior passenger tested positive for Covid-19. The following morning, 10 people on the ship tested positive for the new form of coronavirus, according to Business Insider.
Despite a month-long quarantine, by late February, 705 people — out of more than 3,000 crew members and guests — tested positive for Covid-19, Japan's Ministry of Health said in a news release.
Treating Covid-19 With Antiviral Drug
NIH lung specialist Childs arrived in Japan on Feb. 16. Of 50 Americans hospitalized in Japan, 14 were selected to receive Gilead's experimental coronavirus treatment based on their medical histories. Three Japanese patients also qualified.
All 17 patients are still alive, the Journal said.
Representatives from NIH didn't return requests for comment from Investor's Business Daily.
In an email to IBD, Gilead confirmed the U.S. government is helping it coordinate with local authorities in Japan to use remdesivir "due to the unprecedented burden of patients associated with local transmission as well as the Diamond Princess cruise ship."
Shares of GILD stock touched a two-year high last week on excitement for the potential of remdesivir in coronavirus treatment.
ALLISON GATLIN 04:32 PM ET 03/13/2020
Shares of GILD stock popped Friday on reportedly promising results for its experimental coronavirus treatment in 14 Americans hospitalized in Japan.
The results are some of the earliest for Gilead Sciences' (GILD) remdesivir, an antiviral that was previously under testing for Ebola virus. Now, the biotech company is hoping to use it to treat Covid-19, a form of coronavirus discovered in December in China.
According to the Wall Street Journal, 14 Americans aboard the Diamond Princess cruise ship who contracted Covid-19 were given remdesivir intravenously once a day for 10 days. As of Friday, all 14 were still alive and more than half had recovered.
Five remain critically ill, Rear Adm. Richard Childs, an assistant surgeon general and lung specialist at the National Institutes of Health, reportedly said. The average age of the 14 patients is 75 and all of them were critically ill. The news sent GILD stock airborne Friday.
"Many of them were probably going to die in a short amount of time, and two weeks later nobody has died and more than half of them have recovered," he said. "It's just absolutely amazing. It's going to take us a while to figure out what the impact of the drug has been."
GILD Stock Rises On Coronavirus Treatment
On the stock market today, GILD stock jumped 3.2%, to 70.75. The biotech stock has been volatile as it seeks a coronavirus treatment. Meanwhile, a broader coronavirus correction has slammed the stock market.
Many are pinning their hopes for Covid-19 treatment on remdesivir. Tests of the potential coronavirus treatment are ongoing in China, Japan and the U.S. Amid the broad correction, GILD stock also has a Relative Strength Rating of 92, putting its stock performance in the top 8% of all stocks.
The Diamond Princess cruise ship docked in Japan on Feb. 4 after officials learned a prior passenger tested positive for Covid-19. The following morning, 10 people on the ship tested positive for the new form of coronavirus, according to Business Insider.
Despite a month-long quarantine, by late February, 705 people — out of more than 3,000 crew members and guests — tested positive for Covid-19, Japan's Ministry of Health said in a news release.
Treating Covid-19 With Antiviral Drug
NIH lung specialist Childs arrived in Japan on Feb. 16. Of 50 Americans hospitalized in Japan, 14 were selected to receive Gilead's experimental coronavirus treatment based on their medical histories. Three Japanese patients also qualified.
All 17 patients are still alive, the Journal said.
Representatives from NIH didn't return requests for comment from Investor's Business Daily.
In an email to IBD, Gilead confirmed the U.S. government is helping it coordinate with local authorities in Japan to use remdesivir "due to the unprecedented burden of patients associated with local transmission as well as the Diamond Princess cruise ship."
Shares of GILD stock touched a two-year high last week on excitement for the potential of remdesivir in coronavirus treatment.
Antwort auf Beitrag Nr.: 63.007.424 von carfal am 14.03.20 13:17:45eben!
Das frage ich mich auch?
Wenn hier Remdesivir als Medikation gegen Corona helfen sollte,
wieso geht der Kurs dann jetzt schon nicht durch die Decke???
Das frage ich mich auch?
Wenn hier Remdesivir als Medikation gegen Corona helfen sollte,
wieso geht der Kurs dann jetzt schon nicht durch die Decke???
oops, sorry für die Fehler oben, wer sie findet, darf sie behalten
Antwort auf Beitrag Nr.: 63.006.929 von marty44 am 14.03.20 11:58:27Hi!
Könntest Du evtl. kurz zusammenfassen, was das direkt mit Gilead zu tun hat,
bzw. welchen Einfluss dies /das auf die wirtschaftliche Entwicklung für Gilead haben könnte?
Danke & Gruss,
1000kV
Könntest Du evtl. kurz zusammenfassen, was das direkt mit Gilead zu tun hat,
bzw. welchen Einfluss dies /das auf die wirtschaftliche Entwicklung für Gilead haben könnte?
Danke & Gruss,
1000kV
Durchsuchen
22:02 Uhr · Business Wire (engl.) · Gilead Sciences |
05.04.24 · wallstreetONLINE Redaktion · Gilead Sciences |